89bio Inc's Comment on Sales, Marketing and Customers
The European Union's regulatory framework for innovative medicinal products, specifically New Chemical Entities (NCEs), includes defined periods of data exclusivity and marketing exclusivity that impact the market entry of generic, hybrid, or biosimilar products. Data exclusivity lasts for eight years, during which generic applicants cannot rely on the originator's data, followed by a two-year marketing exclusivity period preventing generic product sales. An additional one-year extension is possible if new therapeutic indications are approved within the first eight years. Other companies may market similar products if they submit their own complete data. The European Commission has proposed reforms to pharmaceutical legislation, including shortening data exclusivity periods; however, no final version or enforcement date has been established. The European Parliament approved its position on the reform in April 2024, but no further legislative action has occurred.
The latest in clinical trial development comes to the forefront as 89bio Inc., a premier clinical-stage biopharmaceutical company, recently initiated the Phase 3 ENLIGHTEN-Cirrhosis study of pegozafermin. This trial is a ground-breaking first-step in the pursuit of advanced therapies for Metabolic Dysfunction-Associated Steatohepatitis (MASH) patients with compensated cirrhosis (F4). The pegozafermin has made history as the first fibroblast growth factor 21 (FGF21) analog introduced into a Phase 3 testing stage for MASH.Primarily addressing Nonalcoholic Steatohepatitis (NASH), 89bio Inc. has additionally implemented a strategic alignment with both the US Food and Drug Administration (FDA) and the European Me...
aims to present the latest scientific advancements in the field of medicine in order to keep healthcare professionals updated on potential breakthroughs. In this article, we will analyze two recent publications related to the Phase 3 ENLIGHTEN-Fibrosis trial and the ENLIVEN Phase 2b trial of pegozafermin conducted by 89bio. These studies focus on the treatment of non-cirrhotic MASH patients with fibrosis stage F2-F3 and may have a significant impact on the pharmaceutical industry.1. Phase 3 ENLIGHTEN-Fibrosis Trial:In the first article, 89bio initiates the Phase 3 ENLIGHTEN-Fibrosis trial of pegozafermin in non-cirrhotic MASH patients with fibrosis. The study aims to evaluate the effectiveness of pegozaferm...
In a significant development for 89bio Inc, the biopharmaceutical company has successfully reached alignment with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on the Phase 3 program for its novel drug candidate, Pegozafermin, for the treatment of Nonalcoholic Steatohepatitis (NASH). This alignment paves the way for the initiation of the program in the first half of 2024. Notably, this achievement also includes the establishment of an accelerated approval pathway for both F4 and F2-F3 NASH patients, measured by histology. Alignment on Key Development Strategy: The alignment attained by 89bio with regulatory authorities on crucial elements of the NA...
89bio Inc’s Comment on Sales, Marketing and Customers
The European Union's regulatory framework for innovative medicinal products, specifically New Chemical Entities (NCEs), includes defined periods of data exclusivity and marketing exclusivity that impact the market entry of generic, hybrid, or biosimilar products. Data exclusivity lasts for eight years, during which generic applicants cannot rely on the originator's data, followed by a two-year marketing exclusivity period preventing generic product sales. An additional one-year extension is possible if new therapeutic indications are approved within the first eight years. Other companies may market similar products if they submit their own complete data. The European Commission has proposed reforms to pharmaceutical legislation, including shortening data exclusivity periods; however, no final version or enforcement date has been established. The European Parliament approved its position on the reform in April 2024, but no further legislative action has occurred.
Sources:
89bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: 89bio Inc’s corporate clients.
For your research, we’ve provided 9 tables on 89bio Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
